Redefining Fluid Control: 

Advancements in diagnosis, monitoring, and management of anatomical outcomes in wAMD and
Beovu (brolucizumab) Real World Data.

Wednesday 25th May 2022 | 18:30 – 20:30 BST

This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Ltd.

UK | May 2022 | 212948

Your attendance at the event is governed by our Healthcare Professional Event Attendance Terms. By attending the event, you are agreeing to be bound by such terms.

Adverse events should be reported. Reporting forms and information can be found at (UK).

Adverse events should also be reported to Novartis via or online through the pharmacovigilance intake (PVI) tool at

If you have a question about a product, please contact Medical Information on 01276 698370 or by email at